Представленная информация о лекарственных средствах предназначена исключительно для ознакомления и не является офертой, рекламой или инструкцией по применению. Продажа, доставка и назначение препаратов через сайт не осуществляются. По вопросам применения препарата вы можете записаться на очный прием или онлайн-консультацию у профильного специалиста нашей клиники.
MESTION (KALIMIN) 60 mg (ITALY)
9у.е.
Dosage form: tablets.
Pharmacotherapeutic group: drugs affecting the central nervous system.
Clinical characteristics
Indications:
• Myasthenia gravis;
• Myasthenic syndrome (Lambert-Eaton myasthenic syndrome) as part of combination therapy with guanidine.
Contraindications:
The drug is contraindicated in:
• hypersensitivity to the components;
• mechanical obstruction of the gastrointestinal tract or urinary tract;
• bronchial asthma, spastic bronchitis, iritis, breastfeeding.
Method of administration and dosage:
Dosage and duration of treatment are determined individually by the physician.
Myasthenia gravis:
1–3 tablets 3–4 times a day (180–720 mg per day).
Myasthenic syndrome:
Initial dose — 180–720 mg per day in 3–4 doses. If necessary, guanidine is added at a dose of 375–1000 mg.
For patients with kidney diseases:
Reduction of dosage or increase in intervals between doses.
Side effects:
• Nausea, vomiting, diarrhea, abdominal pain;
• Bradycardia, hypotension;
• Increased salivation, bronchospasm;
• Increased sweating, skin rashes.
Overdose:
May cause cholinergic crisis. Treatment: discontinuation of the drug, gastric lavage, administration of atropine sulfate.
Use during pregnancy and breastfeeding:
Prescribed only after risk assessment. The drug is excreted in breast milk, so breastfeeding should be discontinued.
Children:
Not used for the treatment of children.
Precautions:
Use with caution in cases of peptic ulcer, heart diseases, bradycardia, diabetes mellitus.
Interaction with other drugs:
Enhances the action of parasympathomimetics and anticholinesterase drugs. May reduce the effect of corticosteroids and some antibiotics.
Pharmacological properties:
• Pharmacodynamics: inhibits cholinesterase, enhances the action of acetylcholine.
• Pharmacokinetics: maximum concentration is reached in 1.7–3.2 hours. Excreted mainly by the kidneys.
Pharmaceutical characteristics:
White tablets, biconvex, elongated with a score line.
Shelf life: 3 years. After opening the bottle — 6 months.
Storage conditions:
Store at a temperature not exceeding 30°C in a place inaccessible to children.
Pack contains 20 tablets.
Pharmacotherapeutic group: drugs affecting the central nervous system.
Clinical characteristics
Indications:
• Myasthenia gravis;
• Myasthenic syndrome (Lambert-Eaton myasthenic syndrome) as part of combination therapy with guanidine.
Contraindications:
The drug is contraindicated in:
• hypersensitivity to the components;
• mechanical obstruction of the gastrointestinal tract or urinary tract;
• bronchial asthma, spastic bronchitis, iritis, breastfeeding.
Method of administration and dosage:
Dosage and duration of treatment are determined individually by the physician.
Myasthenia gravis:
1–3 tablets 3–4 times a day (180–720 mg per day).
Myasthenic syndrome:
Initial dose — 180–720 mg per day in 3–4 doses. If necessary, guanidine is added at a dose of 375–1000 mg.
For patients with kidney diseases:
Reduction of dosage or increase in intervals between doses.
Side effects:
• Nausea, vomiting, diarrhea, abdominal pain;
• Bradycardia, hypotension;
• Increased salivation, bronchospasm;
• Increased sweating, skin rashes.
Overdose:
May cause cholinergic crisis. Treatment: discontinuation of the drug, gastric lavage, administration of atropine sulfate.
Use during pregnancy and breastfeeding:
Prescribed only after risk assessment. The drug is excreted in breast milk, so breastfeeding should be discontinued.
Children:
Not used for the treatment of children.
Precautions:
Use with caution in cases of peptic ulcer, heart diseases, bradycardia, diabetes mellitus.
Interaction with other drugs:
Enhances the action of parasympathomimetics and anticholinesterase drugs. May reduce the effect of corticosteroids and some antibiotics.
Pharmacological properties:
• Pharmacodynamics: inhibits cholinesterase, enhances the action of acetylcholine.
• Pharmacokinetics: maximum concentration is reached in 1.7–3.2 hours. Excreted mainly by the kidneys.
Pharmaceutical characteristics:
White tablets, biconvex, elongated with a score line.
Shelf life: 3 years. After opening the bottle — 6 months.
Storage conditions:
Store at a temperature not exceeding 30°C in a place inaccessible to children.
Pack contains 20 tablets.
